; The Future of Global Vaccines - Market Forecasts to 2016, Stockpile Analysis, Competitive Benchmarking and Pipeline Analysis
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

The Future of Global Vaccines - Market Forecasts to 2016, Stockpile Analysis, Competitive Benchmarking and Pipeline Analysis

VIEWS: 442 PAGES: 91

Summary GBI Research, the leading business intelligence provider, has released its latest research “The Future of Global Vaccines - Market Forecasts to 2015, Stockpile Analysis, Competitive Benchmarking and Pipeline Analysis”, which provides insights on the global vaccines sales, volume and price forecasts to 2015. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global vaccines market. The report analyzes the markets for vaccines in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope The scope of this report includes: - Annualized market data for the global vaccines market from 2000 to 2008, forecast forward to 2015. - Analysis of the metabolic disorder therapeutics market in the leading geographies of the world. This includes the US, the UK, Germany, France, Italy, Spain, and Japan - Market characterization data on the global vaccines market including market size, market share and annual cost of vaccination. - Key drivers and restraints that have a significant impact on the market - Competitive landscape of the global vaccines market. The key companies studied in this report are Novartis AG, Sanofi Pasteur, Merck & Co, GlaxoSmithKline and Pfizer Inc. - Key M&A activities and licensing agreements that have taken place between 2008 and 2009 in the global vaccines market. Reasons to buy The report will aid business development and marketing executives strategizing their product launches: - Build effective strategies to launch their pipeline products by identifying potential geographies. - Explo

More Info
  • pg 1
									   The Future of Global Vaccines - Market Forecasts to 2016,
      Stockpile Analysis, Competitive Benchmarking and
                      Pipeline Analysis
 Reference Code: GBIHC025MR                                                                                       Publication Date: December 2009


                                  By 2016, the Global Vaccines Market is Expected to Generate More Than
   The global vaccines
   market was valued at $24
                                  Twice the Annual Revenue of 2009
   billion in 2009 and is         The global vaccines industry was valued at $24 billion in 2009 and is expected to reach $52
   expected to more than          billion in 2016 at a Compounded Annual Growth Rate (CAGR) of 11.5%. The vaccines market,
   double in revenues by          which was once considered a low-profit segment of the top players’ portfolios, showed a
   2016                           turnaround after the resounding success of Prevnar, the first blockbuster vaccine. The ability of
                                  vaccines to generate high revenues and profits despite being priced at a premium has proven
                                  attractive to both existing players in the market and to big pharmaceutical companies who have
                                  been watching the development of the market with interest.

                                    Vaccines Market, Global, Revenue Forecasts ($bn), (2007-2016)

                                                      60




                                                      50



                                                                                CAGR (2009-2016) - 11.5%
                                                      40
                                      Revenue ($bn)




                                                      30




                                                      20




                                                      10




                                                       0
                                                           2007   2008   2009       2010      2011         2012     2013    2014    2015      2016


                                    Source: GBI Research


                                  The surge in revenues and growth rates came at a time when the pharmaceutical industry was
                                  under huge pressure from patent expiries and weakened pipelines. The pharmaceutical industry
                                  has been intent on strengthening their revenue streams and streamlining operations through lay-
                                  offs and shutdowns of manufacturing and R&D operations. The success of premium priced
                                  vaccines such as Prevnar, Gardasil, and Cervarix has prompted big pharmaceutical players such
                                  as Pfizer and AstraZeneca to invest in the vaccines industry which promises safe revenues due
                                  to a lack of threat from generics.

                                  The Vaccines Industry is Looking to Increase its Revenues Through the
                                  Introduction of Novel Vaccines and Indication Expansions for Established
                                  Products
                                  GBI Research analyzes that the market dynamics in the current vaccines industry reflects a shift
                                  towards a functional model that is characteristic of the conventional pharmaceutical industry. A
                                  number of innovative vaccines are in development and have been introduced which have


The Future of Global Vaccines - Market Forecasts to 2016,                                                           GBIHC025MR/Published DEC 2009
Stockpile Analysis, Competitive Benchmarking and Pipeline                                                                                         Page 1
Analysis                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                  focused on product differentiation as a means to success. The influenza vaccines market has a
                                  number of vaccines which are considered commodities due to a lack of differentiation. However,
                                  companies are using new vaccine technologies in an effort to increase the prices and increase
                                  profits from the segment. Also, vaccine players are looking to utilize the brand equity of
                                  successful vaccines in generating more revenues from a disease segment. Vaccines such as
                                  Prevnar and Gardasil, which are generating more than $1 billion a year, are being extended for
                                  preventing more related diseases with the aim of adding to the existing revenue streams.
                                  Prevnar, which is a 7-valent vaccine, preventing against seven serogroups, is being developed
                                  as Prevnar-13 to prevent against an additional six serogroups. Gardasil, which was originally
                                  approved for the prevention of four strains of human papillomavirus, is now being developed for
                                  the prevention of nine strains. Product extension strategies which are commonplace in the
                                  pharmaceutical industry are now being used extensively in the vaccines industry to benefit from
                                  the existing popularity of a successful brand. The vaccines industry is expected to use lifecycle
                                  management strategies to full effect in order to retain and improve revenues from their portfolio.

                                  Licensing and Alliance Agreements Accounted for 81% of the M&A and
                                  Licensing Landscape
                                  GBI Research analyzes that licensing and co-development agreements are characteristic of the
                                  global vaccines market where technologies and development platforms are highly dispersed
                                  amongst small and big companies. Smaller vaccine companies that do not have the financial
                                  muscle to compete against the top vaccine players make use of their technologies to generate
                                  revenues through royalties and through other revenue sharing agreements. Also, a number of
                                  public-private partnerships help the vaccines industry develop interventions for new diseases.

                                    Vaccines Market, Global, M&A Landscape by Deal Type, 2009

                                                                                                    Mergers
                                                                                                     11%


                                                                                                                 Acquisition
                                                                                                                    8%




                                                       Licensing & Alliances
                                                               81%


                                    Source: GBI Research



                                  The global vaccines industry is a difficult industry for smaller companies to succeed in due to the
                                  high development costs required for licensing, acquisitions, marketing and manufacturing.
                                  Vaccine companies with promising candidates in the pipeline engage in out-licensing
                                  agreements with the top players, who in turn provide marketing, sales, and regulatory support.
                                  However, the vaccines industry remains an attractive one for large and small companies alike
                                  due to its potential to generate revenues from smaller disease populations too. Hence, the
                                  vaccines industry is expected to remain highly active in the future fueled by the encouragement
                                  and financing from governments and other health organizations.




The Future of Global Vaccines - Market Forecasts to 2016,                                                   GBIHC025MR/Published DEC 2009
Stockpile Analysis, Competitive Benchmarking and Pipeline                                                                                 Page 2
Analysis                                                                 © GBI Research. This is a licensed product and is not to be photocopied
                                  1      Table of Contents

                                  1      Table of Contents ................................................................................................................ 3
                                      1.1      List of Tables.............................................................................................................. 6
                                      1.2      List of Figures............................................................................................................. 6
                                  2      Introduction .......................................................................................................................... 8
                                  3      GBI Research Report Guidance .......................................................................................... 9
                                  4      The Future of Global Vaccines : Market Overview............................................................. 10
                                      4.1      Vaccine Preventable Diseases................................................................................. 10
                                      4.2      Vaccine Manufacturing Process............................................................................... 10
                                  5      The Future of Global Vaccines: Global Vaccines Market................................................... 12
                                      5.1      Market Forecasts ..................................................................................................... 12
                                         5.1.1     Market Share by Disease Sectors ....................................................................... 13
                                         5.1.2     Market Share by Geography ............................................................................... 14
                                      5.2      Average Cost of Vaccination per Child..................................................................... 14
                                      5.3      Target Population..................................................................................................... 15
                                         5.3.1     Immunization Coverage....................................................................................... 17
                                      5.4      Unmet Needs ........................................................................................................... 19
                                      5.5      Market Trends .......................................................................................................... 20
                                         5.5.1     Immunization Programs....................................................................................... 20
                                         5.5.2     Public-Private Partnerships ................................................................................. 20
                                         5.5.3     Production Capacity ............................................................................................ 20
                                         5.5.4     Reimbursements ................................................................................................. 20
                                      5.6      Drivers...................................................................................................................... 21
                                         5.6.1     Growth will be Driven by Vaccines Targeting New Diseases .............................. 21
                                         5.6.2     Adult Vaccines Segment will Provide Significant Boost to Growth of the Market 21
                                         5.6.3     Pediatric Combination Vaccines will Continue to Drive Growth........................... 22
                                         5.6.4     Availability of Vaccine Technologies That Help Increase Efficacy and Safety will
                                                   Drive Innovation and Growth ............................................................................... 22
                                         5.6.5     Cancer and HIV/AIDS Vaccines Hold Significant Potential for the Future ........... 22
                                      5.7      Barriers..................................................................................................................... 22
                                         5.7.1     Limitations in Production Capacity Delays Realization of Potential ..................... 22
                                         5.7.2     High Initial Capital Investments and Technical Expertise Acts as Entry Barrier .. 22
                                         5.7.3     Lack of Harmonized Regulations Delays Vaccine Launch and Acceptance........ 23
                                  6      The Future of Global Vaccines: The US Vaccines Market ................................................. 24
                                      6.1      Market Overview ...................................................................................................... 24
                                      6.2      Market Forecasts .......................
								
To top